Nicotine is the substance in tobacco that makes smoking addictive. Limited studies suggest it could have protective properties, aiding memory and cognitive function.

However, there is not enough evidence to confirm whether nicotine helps with Alzheimer’s. This is because much of the research around this topic has either been low quality, involved animals instead of humans, or focused on adults who do not have Alzheimer’s.

There is evidence that smoking tobacco has links to Alzheimer’s disease, but nicotine, on its own, could help prevent cognitive decline.

This article examines the nicotine and Alzheimer’s link, considering the implications of these findings in shaping preventive measures and therapeutic interventions.

Tobacco leaves hanging upside down in a curing barn.Share on Pinterest
by Alfian Widiantono/Getty Images

The link between nicotine and Alzheimer’s is not entirely clear. An older review from 2011 could not find enough high quality studies on nicotine and Alzheimer’s studies to evaluate whether it has a beneficial or harmful effect. Additionally, the research that does exist has mixed results.

For example, an older study from 2005 on mice found that long-term nicotine intake affected the regulation of tau, which is a protein that has a role in the development of Alzheimer’s.

However, a 2012 clinical trial involving 74 humans found that people who received nicotine via a patch on the skin for 6 months scored better in cognitive tests. This suggests nicotine helped improve brain function in some ways.

The participants did not have Alzheimer’s, but they did have mild cognitive impairment (MCI), which can sometimes be a precursor to dementia.

As a result, it is currently unclear whether nicotine raises or lowers the risk of cognitive decline or Alzheimer’s disease.

Yes, smoking tobacco, which contains nicotine, does appear to increase the risk of Alzheimer’s disease.

Numerous studies have shown a relationship between smoking and Alzheimer’s. Smoking exposes individuals to a combination of harmful chemicals that cause oxidative stress, inflammation, and vascular damage. These processes contribute to changes in the brain and may accelerate cognitive decline.

There is ongoing research into whether nicotine improves memory, attention, or learning abilities. The Memory Improvement through Nicotine Dosing (MIND) study is among this research. It is a significant trial that is investigating the effects of nicotine in people with mild memory loss or MCI.

In the MIND study, researchers hope to determine if nicotine could delay or prevent the progression of MCI to Alzheimer’s disease. However, the trial is still ongoing, so evidence on this is still fairly limited.

Older research from 2012 on the effects of nicotine in people with MCI did show a favorable effect, with no serious side effects or withdrawal signs during the trial’s 6-month period.

However, while the participants’ test scores improved, the authors note that there was no difference in symptom severity between those who received nicotine and the control group, who received a placebo.

Some researchers argue that nicotine could have a benefit on memory and cognitive impairments in people with Alzheimer’s disease, but this finding mostly derives from theory.

Nicotine could improve cognitive function by activating specific pathways in the brain. Nicotine enhances the activity of an enzyme known as protein kinase B (Akt), which is essential for various cellular processes.

Nicotine also stimulates phosphoinositide 3-kinase and Akt signaling, which regulates processes involved in learning and memory.

However, few trials have put this to the test. A small 2000 trial involving 13 participants with Alzheimer’s found no difference between those who received nicotine and those who had a placebo.

At present, there is not enough evidence that nicotine works as an Alzheimer’s treatment, but there is interest in pursuing research on this.

A 2021 review of previous research argues that the substance could help prevent Alzheimer’s by maintaining cognitive function as a person ages. Further research is necessary to confirm if this works.

Research is also necessary to confirm whether nicotine is safe or easy to tolerate for people with Alzheimer’s, as it can cause side effects. These include impaired sleep, dizziness, nicotine dependence, and digestive symptoms.

No, doctors recommend not self-treating Alzheimer’s with nicotine patches. People need to consult a doctor before starting any new treatment, supplement, or complementary therapy.

Some research suggests nicotine might have cognitive benefits in specific contexts. However, there is no evidence that nicotine patches for quitting smoking are an effective or safe treatment for people with Alzheimer’s.

A doctor can provide personalized medical advice, considering an individual’s medical history, current health status, and existing medical conditions. They can evaluate the potential benefits and risks of nicotine therapy according to the individual’s specific circumstances.

Additionally, a doctor can explore alternative treatment options for cognitive issues or memory impairment that may be more appropriate for the individual’s needs and health goals.

The relationship between nicotine and cognitive function, particularly in the context of Alzheimer’s disease, is complex. While some studies suggest there are potential cognitive benefits of nicotine, others disagree.

The approved treatments for Alzheimer’s remain the standard of care. Individuals considering nicotine therapy need to consult with healthcare professionals to make informed decisions.